Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | KLK1 | P06870 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19430208 | 0.95 | ACKR3 (0.39) | AOC3TP53CHRM3KLKB1KLK1 | |
| SCHEMBL19429904 | 0.93 | KLKB1 (0.39) | HTTAOC3KLKB1KLK1TACR3 | |
| SCHEMBL19430013 | 0.93 | AOC3 (0.37) | AOC3CHRM3TACR3ACKR3PDPK1 | |
| SCHEMBL19430021 | 0.91 | KMT2A (0.38) | AOC3LMNACHRM3KLKB1KLK1 | |
| SCHEMBL19430060 | 0.90 | KMT2A (0.40) | HTTAOC3LMNATP53KLKB1 | |
| SCHEMBL19430193 | 0.89 | AOC3 (0.37) | AOC3LMNAACKR3 | |
| SCHEMBL19430078 | 0.88 | AOC3 (0.38) | AOC3LMNATP53ACKR3 | |
| SCHEMBL19430181 | 0.85 | AOC3 (0.38) | AOC3 | |
| SCHEMBL19430371 | 0.85 | AOC3 (0.39) | AOC3 | |
| SCHEMBL19430304 | 0.85 | SCD5 (0.39) | AOC3ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HTT 3149/4885SMN1; SMN2 1252/4885AOC3 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.